Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Schizophrenia patients diagnosis either with DSM-5 criteria or ICD-10;
PANSS total score ≥70;
Males or Females aged 18-45 years;
With disease course less than 5 years and during their first episode;
≥9 years of education;
Without receiving systematic antipsychotic treatment, or receiving continuous antipsychotic treatment for less than 6 weeks and receiving antipsychotic treatment for less than 6 months in total;
Ability to read and understand Chinese;
Provision of written informed consent
You may not be if
Severe or unstable physical diseases judged by investigators;
Loss of consciousness more than 1 hour due to any reason in the past 1 year;
Current substance misuse (in 3 months) or any substance dependence;
Pregnant or lactating woman;
Patients with attempted suicide history, severe suicidal ideation or behaviour;
Mental retardation;
Contradict to the study drugs;
Patients taken other investigation products in the past 30 days before entry;
Patients ever taken blonanserin before;
Any current medical condition that would interfere with the assessment of efficacy;
Physical symptoms of acute deterioration requiring hospitalization or increased intensive care;
Significant muscle tension or Parkinson's disease;
Clinically significant abnormal laboratory test results (blood, urine, and blood biochemical analysis);
Clinically significant Abnormal electrocardiogram as judged by researchers;
Participants continuously using sedative drugs, or anticholinergic agents within 3 months of the study;
Those who had undergone electroconvulsive therapy within 3 month of the study;
Those who had received long-acting injection treatment within 3 month of the study;
Those who could not swallow medication with water;
Subjects judged by the investigator in charge as inappropriate for the study
Clareo Health | Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
